Skip to Content
Merck
CN
All Photos(1)

Key Documents

N1013

Sigma-Aldrich

Neoagarohexaose

≥95%

Sign Into View Organizational & Contract Pricing

Select a Size

25 MG
¥815.23
100 MG
¥2,744.98

¥815.23

Please contact Customer Service for Availability
All Photos(1)

Select a Size

Change View
25 MG
¥815.23
100 MG
¥2,744.98

About This Item

Empirical Formula (Hill Notation):
C36H56O28
CAS Number:
25023-93-2
Molecular Weight:
936.81
MDL number:
MFCD00133658
UNSPSC Code:
12352201

¥815.23

Please contact Customer Service for Availability

Assay

≥95%

storage temp.

2-8°C

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
76183PHR1455Y0000800
Ascorbic acid 6-palmitate meets USP testing specifications

A1968

Ascorbic acid 6-palmitate

6-O-Palmitoyl-L-ascorbic acid BioXtra, ≥99.0% (RT)

76183

6-O-Palmitoyl-L-ascorbic acid

Ascorbyl Palmitate Pharmaceutical Secondary Standard; Certified Reference Material

PHR1455

Ascorbyl Palmitate

Ascorbyl palmitate European Pharmacopoeia (EP) Reference Standard

Y0000800

Ascorbyl palmitate

biological source

synthetic

biological source

synthetic

biological source

-

biological source

synthetic

assay

95.0-100.5%

assay

≥99.0% (RT)

assay

-

assay

-

form

powder

form

powder

form

-

form

solid

application(s)

pharmaceutical (small molecule)

application(s)

-

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

Quality Level

200

Quality Level

200

Quality Level

300

Quality Level

-

color

light yellow

color

white to faint yellow

color

-

color

-

Other Notes

Mixed anomers

Preparation Note

Prepared enzymatically from agar.
  • Specification Sheet

    • Choose from one of the most recent versions:

    Certificates of Analysis (COA)

    Lot/Batch Number
    058H3396
    057F0332
    057F03322
    117H3398
    028H5207

    Don't see the Right Version?

    If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

    Search for a COA

    Already Own This Product?

    Find documentation for the products that you have recently purchased in the Document Library.

    Visit the Document Library

    John R Guyton et al.
    Journal of the American College of Cardiology, 62(17), 1580-1584 (2013-08-07)
    This study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes in this secondary analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial. During a
    Koon K Teo et al.
    Stroke, 44(10), 2688-2693 (2013-07-25)
    In Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, addition of extended-release niacin (ERN) to simvastatin in participants with established cardiovascular disease, low high-density lipoprotein cholesterol, and high triglycerides had no incremental
    Paul M Lavigne et al.
    Journal of the American College of Cardiology, 61(4), 440-446 (2012-12-26)
    This study sought to assess the efficacy of niacin for reducing cardiovascular disease (CVD) events, as indicated by the aggregate body of clinical trial evidence including data from the recently published AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High
    Beat Müller et al.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 20(2), 181-195 (2003-10-11)
    A novel methodology for establishing a pharmacological dose-effect relationship of methyl nicotinate, hexyl nicotinate and nicotinic acid acting as peripheral vasodilators in the skin following topical application is investigated. This methodology involves the estimation of the unbound drug concentration in
    Martina Lukasova et al.
    Trends in pharmacological sciences, 32(12), 700-707 (2011-09-29)
    Nicotinic acid (niacin) has been used for decades to prevent and treat atherosclerosis. The well-documented antiatherogenic activity is believed to result from its antidyslipidemic effects, which are accompanied by unwanted effects, especially a flush. There has been renewed interest in
    View All Related Papers

    Articles

    Poly(Amino Acid) Block Copolymers for Drug Delivery and other Biomedical Applications

    Humankind has utilized protein materials throughout its existence, starting with the use of materials such as wool and silk for warmth and protection from the elements and continuing with the use of recombinant DNA techniques to synthesize proteins with unique and useful properties.

    Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

    Contact Technical Service